S&P Futures
3,843.50 +9.50 (+0.25%) Dow Futures
31,006.00 +70.00 (+0.23%) Nasdaq Futures
11,847.75 +39.25 (+0.33%) Russell 2000 Futures
1,744.90 +3.20 (+0.18%) Crude Oil
101.56 +2.06 (+2.07%) Gold
1,768.00 +4.10 (+0.23%)
BioRestorative Therapies, Inc. (BRTX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 3.3700 |
| Open | 3.4500 |
| Bid | 0.0000 x 800 |
| Ask | 0.0000 x 1200 |
| Day's Range | 3.4000 - 3.4990 |
| 52 Week Range | 2.7500 - 32.0000 |
| Volume | |
| Avg. Volume | 20,994 |
| Market Cap | 12.634M |
| Beta (5Y Monthly) | 77.95 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -17.7440 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for BRTX
Related Research
- BioRestorative Therapies, Inc.Analyst Report: Pinterest, Inc.Pinterest is an online product and idea discovery platform that helps users gather ideas on everything from recipes to cook to destinations to travel to. Founded in 2010, the platform consists of a largely female audience, at roughly two thirds of its more than 365 million monthly active users. The company generates revenue by selling digital ads and is now rolling out more in-platform e-commerce features.RatingFair ValueEconomic Moat7 days agoMorningstar
- GlobeNewswire
BioRestorative Therapies Announces First Patient Enrolled for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)
First Patient Enrollment Milestone Completed MELVILLE, NY., June 30, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that the first patient has been enrolled in the Company’s Phase 2 clinical trial evaluating the safety and preliminary efficacy of BRTX-100, an autologous bone marrow-derived mesenchymal stem cell targeting chronic lumbar disc disease (cLDD). T
- GlobeNewswire
BioRestorative Therapies Announces Clinical Trial Contract with Second Site for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)
MELVILLE, NY., June 22, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced it has reached an agreement with its second clinical site for its Phase 2 clinical trial targeting chronic lumbar disc disease (cLDD). The Center for Clinical Research, which is located in North Carolina, is BioRestorative’s second clinical trial contract executed. BioRestorative’s Phase
- Benzinga
EXCLUSIVE: BioRestorative Selects Second Site For Its Lumbar Disc Disease Study
BioRestorative Therapies Inc (NASDAQ: BRTX) has selected the Center for Clinical Research in North Carolina as the company's second contract for its Phase 2 trial targeting chronic lumbar disc disease (cLDD). BioRestorative develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. What Happened: The Phase 2 trial will evaluate the safety and preliminary efficacy of a single dose intradiscal injection of the company's autologous investigational stem cell
